Posted by Michael Wonder on 28 Jul 2022
To promote innovation, Congress and companies should support drug development cost disclosure
28 July 2022 - Congress should pass the proposed Pharmaceutical Research Transparency Act of 2022 to mandate drug companies provide detailed and disaggregated clinical trial costs to the public.
Strong arguments have been advanced in support of this act as providing information essential in determining when and whether research costs justify high drug prices and price increases.
